Incyte Corp
- Last sale
- Nov 12, 2026 · -0.44%
- Market cap
- $24.80B
- 203.83M shares
- Filings
- 1,093
Q3 2026+21.2% FY25 yoy
Q3 2026+3,845.0% FY25 yoy
Q3 2026+2,368.6% FY25 yoy
FY 2022derived+56.9% FY22 yoy
Q3 2026+4,173.3% FY25 yoy
Q3 2026+83.5% FY25 yoy
- $24.80B
- 61.5×
- 4.1×
- 4.4×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $5,141,242,000 | reported | |
| FY 2024 | 2024-12-31 | $4,241,217,000 | reported | |
| FY 2023 | 2023-12-31 | $3,695,649,000 | reported | |
| FY 2022 | 2022-12-31 | $3,394,635,000 | reported | |
| FY 2021 | 2021-12-31 | $2,986,267,000 | reported | |
| FY 2020 | 2020-12-31 | $2,666,702,000 | reported | |
| FY 2019 | 2019-12-31 | $2,158,759,000 | reported | |
| FY 2018 | 2018-12-31 | $1,881,883,000 | reported | |
| FY 2017 | 2017-12-31 | $1,536,216,000 | reported | |
| FY 2016 | 2016-12-31 | $1,105,719,000 | reported | |
| FY 2015 | 2015-12-31 | $753,751,000 | reported | |
| FY 2014 | 2014-12-31 | $511,495,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $0.00 | $0.00 | — | 199.01M sh | +2.8% | — |
| FY2024 | — | $2.00B | $2.00B | — | 193.52M sh | −13.8% | — |
| FY2023 | — | $0.00 | $0.00 | — | 224.53M sh | +0.7% | — |
| FY2022 | — | $0.00 | $0.00 | — | 222.97M sh | +0.7% | 0.0% |
Segments
LineFY2025ShareChange
United States$4.80B93%+20.8%
Europe$323.73M6.3%+24.3%
Other countries$17.57M0.3%+182.7%
Europe and Japan———
Total$5.14B
Commercial physical & biological research
Incyte Corp is the 3rd largest of the 17 covered companies the SEC files under this code, by revenue. SIC 8731
CompanyRevenueGrowthNet marginMarket cap
IQVIQVIA Holdings Inc.$16.3B5.9%8.3%$44.7BICLRIcon PLC$8.3B0.8%2.8%—
INCYIncyte Corp (this company)$5.1B21.2%25.0%$24.8B
CRLCharles River Laboratories International, Inc.$4.0B0.9%3.6%$16.9BMEDPMedpace Holdings, Inc.$2.5B20.0%17.8%$18.4BNRCNRC Health$137.4M4.0%8.4%$566.4MMXCTMaxcyte, Inc.$33.0M14.5%135.1%$121.8MOABIOmniAb, Inc.$18.7M29.3%347.0%$721.3MFOXOFoxo Technologies Inc.$16.4M304.0%75.9%—Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Incyte Corp · CIK 879169 · Engraved from SEC EDGAR